Welcome to our dedicated page for Indivior Pharmaceuticals SEC filings (Ticker: INDV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Indivior PLC (NASDAQ: INDV) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a pharmaceutical issuer focused on opioid use disorder (OUD) treatments, Indivior uses its filings to report financial results, strategic initiatives, governance changes, and key legal and regulatory matters.
Investors can review Form 8-K current reports in which Indivior details material events such as quarterly financial results, updates on the Indivior Action Agenda, restructuring charges, optimization of its Rest of World business, and changes to executive compensation or board composition. Other 8-K items describe the company’s intent to redomicile from the U.K. to Delaware, shareholder approvals of a scheme of arrangement and amended articles of association, and the conclusion of a legacy U.S. Department of Justice resolution agreement.
Through its periodic reports (Forms 10-K and 10-Q, when available on EDGAR), readers can examine segment performance, revenue composition, R&D spending, and risk factors related to Indivior’s OUD-focused portfolio, including SUBLOCADE, SUBOXONE Film, PERSERIS, and OPVEE. These filings also typically include detailed discussions of non-GAAP measures such as adjusted EBITDA and non-GAAP operating expenses, along with reconciliations to U.S. GAAP metrics.
Stock Titan enhances these documents with AI-powered summaries that highlight the most important points in lengthy filings, helping users quickly understand changes in guidance, restructuring actions, legal exposures, or capital structure. Real-time updates from EDGAR mean that new Indivior filings, including any future proxy statements on executive compensation and Form 4 insider transaction reports, are surfaced promptly.
By using this page, investors, analysts, and other stakeholders can efficiently navigate Indivior’s SEC reporting history, monitor developments in its OUD pharmaceutical business, and interpret the financial and governance implications of its regulatory disclosures.
Indivior Pharmaceuticals’ Chief Legal Officer Jeffrey W. Burris reported new equity awards. He acquired 26,897 shares of common stock on February 10, 2026 through a grant of restricted stock units with a stated value of $0 per share, bringing his direct holdings to 27,657 common shares.
He was also granted 104,300 performance stock units on February 9, 2026. These units relate to a conditional award originally granted on March 3, 2023, for 104,300 shares, with performance conditions certified on February 9, 2026 and vesting on March 3, 2026, subject to continued employment. The new RSUs vest in three equal annual installments beginning February 10, 2027.
Indivior Pharmaceuticals, Inc. Chief Scientific Officer Christian Heidbreder reported equity awards in the form of stock-based compensation. On February 10, 2026, he acquired, via grant, 33,622 restricted stock units of common stock at a price of $0 and now directly holds 190,762 common shares.
On February 9, 2026, he was also granted 132,565 performance stock units at a price of $0. These performance stock units relate to a conditional award whose performance conditions were certified on February 9, 2026 and are scheduled to vest on March 3, 2026, subject to continued employment. The RSUs vest in three equal annual installments beginning February 10, 2027.
Indivior Pharmaceuticals, Inc. reported that its Chief Commercial Officer, Barry Patrick A, acquired 31,380 shares of common stock on February 10, 2026 through a grant of restricted stock units. These RSUs vest in three equal annual installments starting on February 10, 2027, subject to his continued service with the company.
Indivior Pharmaceuticals, Inc.’s Chief Executive Officer and director Joseph Ciaffoni reported receiving a grant of 79,976 shares of common stock in the form of restricted stock units at a price of $0 per share. Following this equity award, he beneficially owns 135,976 common shares directly.
The RSUs vest in three equal annual installments starting on February 10, 2027, the first anniversary of the grant. Each unit represents the right to receive one share of common stock, contingent on his continued service with the company.
The Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC report beneficial ownership of 3,592,430.80 shares of Indivior Pharmaceuticals, Inc. common stock, representing 2.9% of the class as of the reported date.
The firms report shared voting power over 3,592,395.80 shares and shared dispositive power over 3,592,430.80 shares, with no sole voting or dispositive power. They state the securities are held in the ordinary course of business and not for the purpose of changing or influencing control of Indivior Pharmaceuticals.
Indivior Pharmaceuticals, Inc. director receives equity grant. Director Kingsley Stuart A reported an award of 3,722 shares of common stock on January 26, 2026, recorded at a price of $0 per share as a stock-based grant rather than a purchase.
The grant is in the form of Restricted Stock Units, each representing one future share of common stock. These RSUs vest on the day immediately before the first annual stockholders’ meeting following the grant date, as long as the director continues to serve on that date. After this award, the director beneficially owns 4,642 shares directly.
Indivior Pharmaceuticals director David E. Wheadon reported a grant of 5,955 shares of common stock on January 26, 2026, reflected as an acquisition at a price of $0 per share. After this equity grant, he beneficially owned 20,350 shares in total.
The grant consists of restricted stock units (RSUs), each representing a right to receive one share of common stock. These RSUs vest on the day immediately before the first annual stockholder meeting following the grant date, contingent on his continued service to Indivior through that vesting date.
Indivior Pharmaceuticals director receives equity grant. Director Ryan Barbara was granted 3,722 shares of Indivior Pharmaceuticals, Inc. common stock on January 26, 2026 as a stock-based award at a price of $0 per share. After this grant, Barbara beneficially owns 5,685 common shares in total.
The award is in the form of restricted stock units (RSUs), each representing the right to receive one share of common stock. These RSUs vest on the day immediately before the first annual stockholders’ meeting following the grant date, contingent on Barbara’s continued service to the company through that vesting date.
Indivior Pharmaceuticals director Daniel A. Ninivaggi received an equity grant through restricted stock units. On 01/26/2026 he was awarded 3,722 RSUs, recorded at a price of $0 per unit, increasing his beneficial ownership to 20,645 shares of common stock held directly.
The RSUs each represent a right to receive one share of Indivior common stock. They vest on the day immediately before the first annual meeting of stockholders following the grant date, as long as he continues to serve the company through that vesting date.
Indivior Pharmaceuticals, Inc. director Mark Stejbach reported a grant of 3,722 shares of common stock in the form of Restricted Stock Units on January 26, 2026 at a price of $0 per share. Following this award, he beneficially owns 20,569 common shares in total.
Each RSU represents the right to receive one share of common stock and will vest on the day immediately before the first annual stockholders’ meeting after the grant date, as long as Stejbach continues serving the company through that vesting date.